Search research articles
Contact Us
Filters
Showing results (411-420 of 738) with videos related to
Page
of 74
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the science
Rachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
Journal of Patient-Reported Outcomes
|
June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Page
of 74
Search research articles
Search
Showing results (411-420 of 738) with videos related to
Sort By:
Page
of 74
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the science
Rachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
Journal of Patient-Reported Outcomes
|
June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Page
of 74